Skip to main content
. 2012 Sep 28;2:119–132. doi: 10.2147/DNND.S35790

Figure 3.

Figure 3

Reduction of ARR at 2 years by BG-12 and DMTs approved for MS treatment, as reported in Phase III clinical trials.

Note: Data obtained from different noncomparative trials.3539,86,88,105

Abbreviations: ARR, annualized relapse rate; DMT, disease-modifying treatment; MS, multiple sclerosis; BID, twice a day; TID, three times a day.